Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Entyvio, Rexulti, and Lenvima among 15 More Drugs Picked for IRA Price Talks
January 29, 2026
-
REGULATORY Japan’s Lower House Campaign Begins amid Fragmented Political Set-Up
January 28, 2026
-
REGULATORY Former LDP Lawmakers Outline Drug Policy Priorities in Comeback Bids
January 28, 2026
-
BUSINESS Ajinomoto Builds Presence in ADC CDMO Business with Proprietary Technology
January 27, 2026
-
REGULATORY Japan Panel OKs AbbVie’s Aquipta, Ipsen’s Sohonos, and Novo’s IcoSema for Approval
January 26, 2026
-
BUSINESS Will Unlisted AGs Rush for June Listing or Be Left on Ice?
January 23, 2026
-
REGULATORY Japan’s 1st Xolair Biosimilar Likely from Celltrion as JAN Is Assigned
January 23, 2026
-
REGULATORY DPP Vows to Scrap Off-Year Drug Price Revisions in Election Platform
January 23, 2026
-
REGULATORY Japan Health Minister Says Early Call on FY2027 Off-Year Revision Improves Predictability
January 22, 2026
-
REGULATORY PMDA Chief Vows Stronger Support for Drug Discovery, Orphan Designations
January 21, 2026
-
ORGANIZATION OTC Industry Head Urges Caution on Extra Charges for “OTC-Like” Drugs
January 20, 2026
-
REGULATORY AMED, JPMA Poised to Embed Pharma Expertise in Drug Discovery
January 20, 2026
-
REGULATORY Japan’s Lower House Poll Set for Feb. 8 after Takaichi Calls Snap Vote
January 20, 2026
-
REGULATORY Bosulif, 4 Other Drugs Escape April Re-Pricing as “Spillover” Scrapped; Lixiana, Entresto Brace for Cuts
January 19, 2026
-
REGULATORY Expert Calls for Full Verification of CEA Guidelines and Analytical Frameworks
January 16, 2026
-
REGULATORY Japan Sets New Pricing Rules for Conditionally Approved Regenerative Medicines, Starting with Elevidys
January 15, 2026
-
BUSINESS Rohto to Roll Out 3- or 4-Day Workweek Option from April to Spur Growth, Retention
January 15, 2026
-
ORGANIZATION Pharma FTC Clarifies “Simple Beverages” under New Food Rules
January 14, 2026
-
REGULATORY Japan Panel to Review AbbVie’s Aquipta, Ipsen’s Sohonos on January 23
January 13, 2026
-
REGULATORY MHLW Pharma Director Says Uniform Drug Price Hike “Not Realistic,” Targeted Support Preferred
January 9, 2026
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…